Basal Insulin Analogs Don't Cut Hypoglycemia-Linked ER Visits

Share this content:
Basal Insulin Analogs Don't Cut Hypoglycemia-Linked ER Visits
Basal Insulin Analogs Don't Cut Hypoglycemia-Linked ER Visits

THURSDAY, July 12, 2018 (HealthDay News) -- Initiation of a basal insulin analog versus human neutral protamine Hagedorn (NPH) insulin is not associated with reduction in the risk of hypoglycemia-related emergency department visits or hospital admissions, according to a study published in the July 3 issue of the Journal of the American Medical Association.

Kasia J. Lipska, M.D., from the Yale University School of Medicine in New Haven, Conn., and colleagues compared the rates of hypoglycemia-related emergency department visits or hospital admissions associated with initiation of long-acting insulin analogs versus human NPH insulin in a retrospective observational study. Data were included for 25,489 patients with type 2 diabetes who initiated basal insulin therapy.

The researchers found that there were 39 hypoglycemia-related emergency department visits or hospital admissions among 1,928 patients who initiated insulin analogs, compared with 354 hypoglycemia-related emergency department visits or hospital admissions among 23,561 patients who initiated NPH insulin (11.9 versus 8.8 events per 1,000 person-years) during a mean follow-up of 1.7 years (between-group difference, 3.1 events per 1,000 person-years; 95 percent confidence interval, −1.5 to 7.7; P = 0.07). The adjusted hazard ratio was 1.16 for hypoglycemia-related emergency department visits or hospital admissions associated with insulin analog use among 4,428 patients matched by propensity score. Within one year of insulin initiation, hemoglobin A1c levels decreased from 9.4 to 8.2 percent and from 9.4 to 7.9 percent after initiation of insulin analogs and NPH insulin, respectively.

"The use of basal insulin analogs in usual practice settings may not be associated with clinical advantages for these outcomes," the authors write.

Two authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves First Customizable Insulin Pump

FDA Approves First Customizable Insulin Pump

Product works by delivering insulin under the skin at set or variable rates

Sepsis Common in Terminal Hospitalizations, Discharges

Sepsis Common in Terminal Hospitalizations, Discharges

Most common underlying causes of death in sepsis are solid and hematologic cancers, chronic heart disease

Fewer Older Men Assessed, Treated for Osteoporosis

Fewer Older Men Assessed, Treated for Osteoporosis

Fewer older men than women, even with higher risk, undergo DXA screening, 25(OH)D measurement

is free, fast, and customized just for you!




Already a member?

Sign In Now »